Since 1985, Dr. Welsh’s research has focused on the role of nutrition and hormones in chronic disease (specific projects have focused on bone health, diabetes, obesity and cancer). She is especially recognized for her studies on the role of nutrients, including vitamin D and vitamin K, in the prevention and treatment of breast cancer. Dr. Welsh’s expertise spans the areas of cell biology, nutrition, cell biology and genomics. She received her Ph.D. in Nutritional Biochemistry at Cornell University and has held appointments at the University of Ottawa (Canada), the W. Alton Jones Cell Science Center in Lake Placid, NY and the University of Notre Dame, where she became the first female Full Professor in the 150 year history of the Department of Biological Sciences. Dr. Welsh is currently a SUNY Distinguished Professor at the University at Albany in the School of Public Health where she directs a research lab focused on diet and cancer. Dr. Welsh has been awarded more than $10 million in research funding from the National Cancer Institute, the American Institute for Cancer Research, the USDA CREES program, the Susan G. Komen Foundation, and the DOD Breast Cancer Research Program, among others. Dr. Welsh serves on multiple grant review panels and is a member of the Editorial Board for the Journal Endocrinology. She frequently presents at international scientific meetings and her work has been featured on high-profile media outlets, including ABC News and Good Morning America. Dr. Welsh is also an inaugural member of the Board of Directors for the Vitamin D Workshop, Inc, a non-profit organization focused on the biology and health implications of vitamin D, for which she also serves as Webmaster and Chief Financial Officer.

Dr. Welsh serves as the Senior Bioscience Advisor to New Reality Solutions group, which includes Huminn, a leading innovation company focused on solving the health, wellness and sustainable development challenges of our time. In this capacity, Dr. Welsh is also the Senior Bioscience Advisor to miR Scientific, LLC, an Huminn subsidiary focused on the management of disease utilizing the Company’s breakthrough tandem Discovery and High Throughput non-coding RNA platforms.